The Assessment and Treatment of Antipsychotic-Induced Akathisia

被引:37
|
作者
Pringsheim, Tamara [1 ]
Gardner, David [2 ]
Addington, Donald [3 ]
Martino, Davide [4 ]
Morgante, Francesca [5 ,6 ]
Ricciardi, Lucia [7 ]
Poole, Norman [8 ]
Remington, Gary [9 ,10 ]
Edwards, Mark [11 ]
Carson, Alan [12 ]
Barnes, Thomas R. E. [13 ]
机构
[1] Univ Calgary, Dept Clin Neurosci Psychiat Pediat & Community Hl, Calgary, AB, Canada
[2] Dalhousie Univ, Dept Psychiat & Pharm, Halifax, NS, Canada
[3] Univ Calgary, Dept Psychiat, Calgary, AB, Canada
[4] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[5] Univ Messina, Dept Clin & Expt Med, Messina, Italy
[6] St Georges Univ London, Inst Mol & Clin Sci, London, England
[7] St Georges Univ London, Inst Cardiovasc & Cell Sci, London, England
[8] Kings Coll London, Dept Philosophy, London, England
[9] Univ Toronto, CAMH, Schizophrenia Div, Dept Psychiat, Toronto, ON, Canada
[10] Univ Toronto, CAMH, Schizophrenia Div, Dept Psychol Clin Sci, Toronto, ON, Canada
[11] St Georges Univ London, Dept Neurol, London, England
[12] Univ Edinburgh, Div Psychiat, Edinburgh, Midlothian, Scotland
[13] Imperial Coll London, Dept Psychiat, London, England
关键词
antipsychotics; extrapyramidal syndromes; evidence-based medicine; NEUROLEPTIC-INDUCED AKATHISIA; INDUCED MOVEMENT-DISORDERS; LOW-DOSE MIRTAZAPINE; DOUBLE-BLIND; TARDIVE-DYSKINESIA; RATING-SCALE; WITHDRAWAL AKATHISIA; BARNES AKATHISIA; CONTROLLED TRIAL; PLACEBO;
D O I
10.1177/0706743718760288
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Akathisia is a common and distressing neuropsychiatric syndrome associated with antipsychotic medication, characterised by subjective and objective psychomotor restlessness. The goal of this guideline is to provide clinicians with recommendations on the assessment and treatment of akathisia. Methods: We performed a systematic review of therapeutic studies assessing the treatment of antipsychotic-induced extrapyramidal symptoms. Forty studies on akathisia and 4 systematic reviews evaluating the adverse effects of antipsychotics were used in the formulation of recommendations. Studies were rated for methodological quality using the American Academy of Neurology Risk of Bias Classification system. The overall level of evidence classifications and grades of recommendation were made using the Scottish Intercollegiate Guidelines Network framework. Results: As a good practice point, clinicians should systematically assess akathisia with a validated scale before starting antipsychotics and during antipsychotic dosage titration. For the management of akathisia, there was adequate evidence to allow recommendations regarding antipsychotic dose reduction, antipsychotic polypharmacy, switching antipsychotic medication, and the use of adjuvant medications including beta-blockers, anticholinergics, 5HT(2A) antagonists, benzodiazepines, and vitamin B6. Conclusion: The treatment of antipsychotic-induced akathisia should be personalised, with consideration of antipsychotic dose reduction, cessation of antipsychotic polypharmacy, and switching to an antipsychotic with a perceived lower liability for akathisia, before the use of adjuvant medications. The choice of adjuvant medications should favour the more established treatments, with careful consideration of contraindications and side effects. Limitations in the evidence should be acknowledged and prompt cautious prescribing, particularly with respect to the duration of use of adjuvant medications, is warranted.
引用
收藏
页码:719 / 729
页数:11
相关论文
共 50 条
  • [41] Antipsychotic-induced hyperprolactinaemia
    Inder, Warrick J.
    Castle, David
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2011, 45 (10): : 830 - 837
  • [42] Antipsychotic-induced amenorrhea
    Seeman, Mary V.
    JOURNAL OF MENTAL HEALTH, 2011, 20 (05) : 484 - 491
  • [43] Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option
    Rusgis, Matthew M.
    Alabbasi, Afaq Y.
    Nelson, Leigh Anne
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (10) : 862 - 871
  • [44] Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy
    Curran, Rebecca L.
    Badran, Ismail A.
    Peppers, Virginia
    Pedapati, Ernest V.
    Correll, Christoph U.
    DelBello, Melissa P.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2016, 26 (05) : 490 - 491
  • [45] Antipsychotic-induced hyperprolactinemia during acute treatment with antipsychotics
    Lee, BH
    Han, CS
    Kim, YK
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S283 - S283
  • [46] Antipsychotic-Induced Movement Disorders in the ElderlyEpidemiology and Treatment Recommendations
    Michael P. Caligiuri
    Dilip V. Jeste
    Jonathan P. Lacro
    Drugs & Aging, 2000, 17 : 363 - 384
  • [47] Antipsychotic-induced weight gain
    Goudie, AJ
    Cooper, GD
    Halford, JCG
    DIABETES OBESITY & METABOLISM, 2005, 7 (05): : 478 - 487
  • [48] Antipsychotic-induced tardive syndromes
    Fleischhacker W.W.
    Hofer A.
    Jagsch C.
    Pirker W.
    Psota G.
    Rittmannsberger H.
    Seppi K.
    neuropsychiatrie, 2016, 30 (3) : 123 - 130
  • [49] A Case of Antipsychotic-Induced Hypothermia
    Ahearn, Joseph
    JOURNAL OF THE ACADEMY OF CONSULTATION-LIAISON PSYCHIATRY, 2022, 63 : S81 - S82
  • [50] Gabapentin in antipsychotic-induced movements
    Hardoy, MC
    Carta, MG
    Hardoy, MJ
    EUROPEAN PSYCHIATRY, 2000, 15 : 324S - 325S